Korro Bio, Inc. (KRRO)
9.44
+0.53
(+5.95%)
USD |
NASDAQ |
Oct 20, 16:00
9.44
0.00 (0.00%)
After-Hours: 06:23
Korro Bio Enterprise Value : 66.00M for Oct. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 20, 2026 | 66.00M |
| October 19, 2026 | 58.20M |
| October 16, 2026 | 52.03M |
| October 15, 2026 | 64.09M |
| October 14, 2026 | 57.76M |
| October 13, 2026 | 56.73M |
| October 12, 2026 | 64.97M |
| October 09, 2026 | 76.59M |
| October 08, 2026 | 82.76M |
| October 07, 2026 | 81.44M |
| October 06, 2026 | 70.70M |
| October 05, 2026 | 73.79M |
| October 02, 2026 | 68.94M |
| October 01, 2026 | 69.97M |
| September 30, 2026 | 72.91M |
| September 29, 2026 | 67.76M |
| September 28, 2026 | 67.03M |
| September 25, 2026 | 67.91M |
| September 24, 2026 | 67.91M |
| September 23, 2026 | 71.73M |
| September 22, 2026 | 79.23M |
| September 21, 2026 | 73.94M |
| September 18, 2026 | 74.53M |
| September 17, 2026 | 100.70M |
| September 16, 2026 | 130.56M |
| Date | Value |
|---|---|
| September 15, 2026 | 134.08M |
| September 14, 2026 | 131.29M |
| September 11, 2026 | 130.26M |
| September 10, 2026 | 119.23M |
| September 09, 2026 | 117.32M |
| September 08, 2026 | 125.85M |
| September 04, 2026 | 107.17M |
| September 03, 2026 | 98.06M |
| September 02, 2026 | 103.20M |
| September 01, 2026 | 107.17M |
| August 31, 2026 | 110.85M |
| August 28, 2026 | 117.03M |
| August 27, 2026 | 122.17M |
| August 26, 2026 | 128.35M |
| August 25, 2026 | 129.08M |
| August 24, 2026 | 119.38M |
| August 21, 2026 | 121.00M |
| August 20, 2026 | 117.76M |
| August 19, 2026 | 132.32M |
| August 18, 2026 | 121.58M |
| August 17, 2026 | 120.41M |
| August 14, 2026 | 122.47M |
| August 13, 2026 | 122.61M |
| August 12, 2026 | 123.50M |
| August 11, 2026 | 123.06M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.090B |
| Oncolytics Biotech, Inc. | 58.48M |
| Sangamo Therapeutics, Inc. | 37.32M |
| Sarepta Therapeutics, Inc. | 2.282B |
| Anixa Biosciences, Inc. | 77.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.92M |
| Total Expenses (Quarterly) | 18.92M |
| EPS Diluted (Quarterly) | -1.074 |
| Earnings Yield | -106.0% |
| Normalized Earnings Yield | -78.82 |